linifanib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702998
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).

Literature References
PubMed ID Title Journal Year
21471285 The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway

Hernandez-Davies, JE, Zape, JP, Landaw, EM, Tan, X, Presnell, A, Griffith, D, Heinrich, MC, Glaser, KB, Sakamoto, KM

Mol. Cancer Ther. 2011
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Nguyen, B, Williams, AB, Young, DJ, Ma, H, Li, L, Levis, M, Brown, P, Small, D

Oncotarget 2017
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!